Hair Loss

Damn this is some great info here! Really useful too, since I've noticed that my hair is beginning to creep backwards. I mean its been happening slowly and steadily for the last year or so, but It's particularly worrying because I don't believe I should be loosing hair so soon in my life. Idk I think it's gotten worse since I got a new overnight job loading trucks. Maybe stress? :confused:

Does anyone here have personal experience with any of the hair treatment formulas posted in the OP? Maybe rogain or propencia? And after you cease use does your hair all fall out again like is rumored?
 
Re: Finasteride [5ARI] Induced/Associated Adverse Effects

Finasteride in the Treatment of Female Pattern (Androgenic) Alopecia

11354


Oliveira-Soares R, JM ES, Correia MP, Andre MC. Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women. Int J Trichology 2013;5(1):22-5. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women Oliveira-Soares R, e Silva J M, Correia M P, André MC - Int J Trichol

BACKGROUND: There is no consensus on the standard treatment options for female pattern androgenetic alopecia (AGA). Efficacy of finasteride in women is controversial. The purpose of this study was to evaluate the clinical efficacy and safety of 5 mg/day oral finasteride in normoandrogenic postmenopausal woman.

MATERIALS AND METHODS: A total of 40 normoandrogenic postmenopausal women with AGA was enrolled in this study. They were treated with oral finasteride 5 mg/day for 18 months. Efficacy was evaluated by patient's satisfaction and global photograph assessment. All the 40 patients completed 18 months of finasteride treatment schedule.

RESULTS: After 6 months, 22 patients referred significant improvement, 12 moderate improvement, and 6 no improvement. Regarding to global photo assessment, 8 patients showed no improvement, 16 showed moderate improvement and 16 showed significant improvements at the 6(th) month. A slight improvement was observed over time from 6 to 12 and 18 months observation. Maintained libido reduction was referred by four patients and liver enzymes increase was observed in one patient. Older patients were more prone to worse response.

DISCUSSION: Finasteride 5 mg/day is effective and safe for the treatment of female AGA in postmenopausal women in the absence of clinical or laboratory signs of hyper-androgenism.
 

Attachments

  • IntJTrichol_2013_5_1_22_114709_u2.jpg
    IntJTrichol_2013_5_1_22_114709_u2.jpg
    143.8 KB · Views: 8
Betsy A, Binitha M, Sarita S. Zinc deficiency associated with hypothyroidism: an overlooked cause of severe alopecia. Int J Trichology 2013;5(1):40-2. Zinc deficiency associated with hypothyroidism: An overlooked cause of severe alopecia Betsy A, Binitha M P, Sarita S - Int J Trichol

Hypothyroidism is a common and well recognized cause of diffuse hair loss. Zinc and other trace elements such as copper and selenium are required for the synthesis of thyroid hormones, and deficiency of these can result in hypothyroidism. Conversely, thyroid hormones are essential for the absorption of zinc, and hence hypothyroidism can result in acquired zinc deficiency. The hair loss attributed to hypothyroidism may not improve with thyroxine unless zinc supplements are added, as demonstrated in our case.
 
Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. Low-level laser (light) therapy (LLLT) for treatment of hair loss - Avci - 2013 - Lasers in Surgery and Medicine - Wiley Online Library

OBJECTIVE: Alopecia is a common disorder affecting more than half of the population worldwide. Androgenetic alopecia, the most common type, affects 50% of males over the age of 40 and 75% of females over 65. Only two drugs have been approved so far (minoxidil and finasteride) and hair transplant is the other treatment alternative. This review surveys the evidence for low-level laser therapy (LLLT) applied to the scalp as a treatment for hair loss and discusses possible mechanisms of actions.

METHODS AND MATERIALS: Searches of PubMed and Google Scholar were carried out using keywords alopecia, hair loss, LLLT, photobiomodulation.

RESULTS: Studies have shown that LLLT stimulated hair growth in mice subjected to chemotherapy-induced alopecia and also in alopecia areata. Controlled clinical trials demonstrated that LLLT stimulated hair growth in both men and women. Among various mechanisms, the main mechanism is hypothesized to be stimulation of epidermal stem cells in the hair follicle bulge and shifting the follicles into anagen phase.

CONCLUSION: LLLT for hair growth in both men and women appears to be both safe and effective. The optimum wavelength, coherence and dosimetric parameters remain to be determined.
 
Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: An update. Indian J Dermatol Venereol Leprol 2013;79(5):613-25. Androgenetic alopecia: An update Kaliyadan F, Nambiar A, Vijayaraghavan S - Indian J Dermatol Venereol Leprol

Androgenetic alopecia (AGA) is one of the commonest reasons for dermatological consultation. Over the last few years our understanding of the pathophysiology of AGA has improved and this has paved way for better diagnostic and therapeutic options. Recent research has dwelled on the role of stem cells in the pathophysiology of AGA and has also identified newer genetic basis for the condition. Dermoscopy/trichoscopy has emerged as a useful diagnostic tool for AGA. While the major treatment options continue to be topical minoxidil, systemic Finasteride and hair transplantations, newer modalities are under investigation. Specific diagnostic and treatment recommendations have also been developed on evidence based principles. This article reviews the recent concepts in relation to AGA. With regards to the pathophysiology we have tried to stress on recent knowledge of the molecular and genetic basis of AGA. We have emphasized on an evidence based approach for treatment and diagnosis.
 
any new hair loss drugs in clinical trials ?

CB-03-01 while not technically being marketed as a hair loss drug, rather as an acne treatment, is most promising looking.

It should be on the market within the next year or two if final trials go well. It's an anti androgen, but it does not have systemic effects due to rapid conversion to an inactive substance from my understanding. And that's not a mistake, they are applying this shit to peoples entire fucking backs, so a the little spot that is your balding head isn't going to go systemic.
 
CB-03-01 while not technically being marketed as a hair loss drug, rather as an acne treatment, is most promising looking.

It should be on the market within the next year or two if final trials go well. It's an anti androgen, but it does not have systemic effects due to rapid conversion to an inactive substance from my understanding. And that's not a mistake, they are applying this shit to peoples entire fucking backs, so a the little spot that is your balding head isn't going to go systemic.


I am unable to find any trials for CB-03-01 for hair loss. There are two trials related to acne. http://clinicaltrials.gov/ct2/results?term=CB-03-01&Search=Search

As the drug is in phase 2, the time to market, IF successful, will be in the order of ~5 years. There is one year alone for submission and review process. This leaves 4 years to complete the phase 2 & 3 trials. Also, as an anti-androgen, its utility in AAS use will be a downside.

Further, I am unable find any studies for hair loss even in animals. Any links to published info is appreciated. There is the following for acne.


Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol 2011;165(1):177-83. Cortexolone 17[]-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0

BACKGROUND: Acne vulgaris is a disorder of the pilosebaceous unit in which the androgens contribute to its onset and persistence. The use of antiandrogens is therefore potentially effective; however, antiandrogens for topical use are not available on the market. Cortexolone 17alpha-propionate (CB-03-01; Cosmo S.p.A, Lainate, Italy) is a new potent topical antiandrogen potentially useful in acne vulgaris.

OBJECTIVES: To evaluate the safety and the topical efficacy of CB-03-01 1% cream in acne vulgaris as compared with placebo and with tretinoin 0.05% cream (Retin-A(R) ; Janssen-Cilag). METHODS: Seventy-seven men with facial acne scored 2-3 according to Investigator's Global Assessment (IGA) were randomized to receive placebo cream (n = 15), or CB-03-01 1% cream (n = 30), or tretinoin 0.05% cream (n = 32) once a day at bedtime for 8 weeks. Clinical efficacy was evaluated every 2 weeks including total lesion count (TLC), inflammatory lesion count (ILC), acne severity index (ASI) and IGA. Safety assessment included local irritancy score, laboratory tests, physical examination, vital signs and recording of adverse events.

RESULTS: CB-03-01 1% cream was very well tolerated, and was significantly better than placebo regarding TLC (P = 0.0017), ILC (P = 0.0134) and ASI (P = 0.0090), and also clinically more effective than comparator. The product also induced a faster attainment of 50% improvement in all the above parameters.

CONCLUSIONS: This pilot study supports the rationale for the use of topical antiandrogens in the treatment of acne vulgaris. CB-03-01 1% cream seems to fit with the profile of an ideal antiandrogen for topical use.
 
Last edited:
CB-03-01 while not technically being marketed as a hair loss drug, rather as an acne treatment, is most promising looking.

It should be on the market within the next year or two if final trials go well. It's an anti androgen, but it does not have systemic effects due to rapid conversion to an inactive substance from my understanding. And that's not a mistake, they are applying this shit to peoples entire fucking backs, so a the little spot that is your balding head isn't going to go systemic.

thanks bro
 
This CB-03-01 ( Cortexolone 17alpha propionate ) looks interesting. Cosmo pharmaceuticals has the patent on this stuff and it looks like they are looking into this for acne treatment. The hairloss treatment always takes the backseat. If women lost hair the way men do I bet there would have been a cure by now. The Kane shop sells this CB-03-01 but the problem is finding a "vehicle" to deliver this stuff to the follicle. It is brutally expensive also.

http://www.cosmopharmaceuticals.com/news/press/pr2010/2010-10-06.aspx
 
A Possible Cure for Baldness, in 3D
A Possible Cure for Baldness, in 3D | Science/AAAS | News


Higgins CA, Chen JC, Cerise JE, Jahoda CAB, Christiano AM. Microenvironmental reprogramming by three-dimensional culture enables dermal papilla cells to induce de novo human hair-follicle growth. Proceedings of the National Academy of Sciences. Microenvironmental reprogramming by three-dimensional culture enables dermal papilla cells to induce de novo human hair-follicle growth

De novo organ regeneration has been observed in several lower organisms, as well as rodents; however, demonstrating these regenerative properties in human cells and tissues has been challenging. In the hair follicle, rodent hair follicle-derived dermal cells can interact with local epithelia and induce de novo hair follicles in a variety of hairless recipient skin sites. However, multiple attempts to recapitulate this process in humans using human dermal papilla cells in human skin have failed, suggesting that human dermal papilla cells lose key inductive properties upon culture. Here, we performed global gene expression analysis of human dermal papilla cells in culture and discovered very rapid and profound molecular signature changes linking their transition from a 3D to a 2D environment with early loss of their hair-inducing capacity. We demonstrate that the intact dermal papilla transcriptional signature can be partially restored by growth of papilla cells in 3D spheroid cultures. This signature change translates to a partial restoration of inductive capability, and we show that human dermal papilla cells, when grown as spheroids, are capable of inducing de novo hair follicles in human skin.
 
Last edited:
[ame=http://www.youtube.com/watch?v=mfLLkmY_t9k]Angela Christiano: New Method for Hair Regeneration - YouTube[/ame]

[2007] Science of hair: The roots of accomplishment
Science of hair: The roots of accomplishment : Article : Nature

"From a New Jersey beauty parlour to cutting-edge genetics by way of her own alopecia, Angela Christiano's life has all been tied up with hair. Helen Pearson meets a woman whose head is full of the stuff that covers it."



New Technique Holds Promise for Hair Growth
http://www.nytimes.com/2013/10/22/science/new-technique-holds-promise-for-hair-loss.html

October 21, 2013
By DENISE GRADY

Scientists have found a new way to grow hair, one that they say may lead to better treatments for baldness.

So far, the technique has been tested only in mice, but it has managed to grow hairs on human skin grafted onto the animals. If the research pans out, the scientists say, it could produce a treatment for hair loss that would be more effective and useful to more people than current remedies like drugs or hair transplants.

Present methods are not much help to women, but a treatment based on the new technique could be, the researchers reported Monday in Proceedings of the National Academy of Sciences.

Currently, transplants move hair follicles from the back of the head to the front, relocating hair but not increasing the amount. The procedure can take eight hours, and leave a large scar on the back of the head. The new technique would remove a smaller patch of cells involved in hair formation from the scalp, culture them in the laboratory to increase their numbers, and then inject them back into the person’s head to fill in bald or thinning spots. Instead of just shifting hair from one spot to another, the new approach would actually add hair.

The senior author of the study is Angela Christiano, a hair geneticist and dermatology professor at Columbia University Medical Center in New York, who has become known for her creative approach to research. Dr. Christiano’s interest in the science of hair was inspired in part by her own experience early in her career with a type of hair loss called alopecia areata. She has a luxuriant amount of hair in the front of her head, but periodically develops bald spots in the back. The condition runs in her family.

In the mid-1990s, she sent photographs of her bald spots to researchers in Pakistan, hoping her plight would persuade them to collaborate with her on a study of a rare genetic disorder there that left people with no hair at all on their heads or bodies. Her strategy worked, and the joint effort identified the gene. In subsequent studies, Dr. Christiano and other colleagues identified multiple genes that play an important role in alopecia areata.

In the current study, Dr. Christiano worked with researchers from Durham University in Britain. They focused on dermal papillae, groups of cells at the base of hair follicles that give rise to the follicles. Researchers have known for more than 40 years that papilla cells from rodents could be transplanted and would lead to new hair growth. The cells from the papillae have the ability to reprogram the surrounding skin cells to form hair follicles.

But human papilla cells, grown in culture, mysteriously lose the ability to make hair follicles form. A breakthrough came when the researchers realized they might be growing the cells the wrong way.

One of Dr. Christiano’s partners from Durham University, Dr. Colin Jahoda, noticed that the rodent papilla cells formed clumps in culture, but the human cells did not. Maybe the clumps were important, he reasoned. So, instead of trying to grow the cells the usual way, in a flat, one-cell layer on a petri dish, he turned to an older method called the “hanging drop culture.”

That method involves putting about 3,000 papilla cells — the number in a typical papilla — into a drop of culture medium on the lid of a dish, and then flipping the lid over so that the drops are hanging upside down.

“The droplets aren’t so heavy that they drip off,” Dr. Christiano said. “The force of gravity just takes the 3,000 cells and draws them into an aggregate at the bottom of the drop.”

The technique made all the difference. The cells seem to need to touch one another in three dimensions rather than two to send and receive the signals they need to induce hair formation.

The researchers took papilla cells from seven men who were undergoing hair transplants, cultured them in hanging drops and then injected them into human skin grafted onto mice. Not just any human skin: to put their ideas to a rigorous test, the researchers made the grafts from a type of skin that is normally 100 percent hairless — foreskins from circumcised infants. A technique that can grow hair on a foreskin has a pretty good chance of growing it on a person’s head, they reasoned.

Indeed, new hair follicles grew in five of the seven grafts, and tests proved that they were human follicles and not mouse ones.

The success, though encouraging, is just a first step, Dr. Christiano cautioned. “At the moment we’re only getting quite a small hair,” she said.

One avenue for further research will be to look at why, in the papilla cells that produced the hair follicles, molecular profiling found that only 22 percent of the genes that normally function in these cells were turned on.

“We were a little surprised by how few,” Dr. Christiano said. “We thought more would be needed.” Perhaps, she said, if more genes could be turned on in the transplanted cells, more hairs, or better quality ones, might result.

Several companies are already experimenting with papilla cells in people, Dr. Christiano said, but they use the cells to try to restore or rejuvenate existing papillae and follicles — not to make new ones. (She has no commercial interests or ties with any of the companies, she said.)

“Inducing a completely new hair is a different challenge,” she said, adding that studies to try doing just that in people are not far off.
 
Last edited:
[Get Out Those Anti-Gravity Boots!]

Hair Loss Weighing on Your Mind? 'Gravity Theory' May Explain Male Pattern Baldness
Hair Loss Weighing on Your Mind? 'Gravity Theory' May Explain Male Pattern Baldness - Yahoo Finance

The effects of gravity may explain the apparently paradoxical effects of testosterone in male pattern baldness, or androgenic alopecia (AGA), according to a special topic paper in Plastic and Reconstructive Surgery-Global Open.

The "force of downward pull caused by the gravity on the scalp skin" is the key contributor to the events leading to progressive hair loss in male pattern baldness, writes Dr. Emin Tuncay Ustuner, a plastic surgeon in Ankara, Turkey. He adds, "The new theory's unparalleled ability to explain even the details of the hair loss process and the formation of the pattern in AGA is apparent."

"Gravity Theory" Helps Explain DHT's Role in Androgenic Alopecia ...

Aging and Testosterone-Related Changes Create 'Vicious Circle' Leading to Hair Loss ...

Dr. Ustuner acknowledges that his "gravity theory" of AGA has met with "notable skepticism and resistance." [YOU THINK!]

But he adds, "Simplifying a very complicated problem is probably the only disadvantage of the theory."


Ustuner ET. Cause of Androgenic Alopecia: Crux of the Matter. Plastic and Reconstructive Surgery Publish Ahead of Print. Cause of Androgenic Alopecia: Crux of the Matter : Plastic and Reconstructive Surgery – Global Open

What is wrong with the current understanding of etiopathogenesis of androgenic alopecia (AGA)?
What is the most important question to ask to understand AGA?
Why is that question skimped?
Which findings are interpreted incorrectly?
Is there anything that has not been discerned about AGA until today?
What are the deceptive factors for investigators?
Is it possible to snap the whole view uninterruptedly in one clear picture?
Answers and an overview with fresh perspectives are provided.
 
Castro RF, Azzalis LA, Feder D, et al. Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model. Clinical and Experimental Dermatology 2012;37(8):909-12. Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model - Castro - 2012 - Clinical and Experimental Dermatology - Wiley Online Library

Insulin-like growth factor (IGF)-1 has shown some interesting results in studies examining its use as a hair-loss treatment. IGF-1 works by regulating cellular proliferation and migration during the development of hair follicles. Hepatotoxicity and myelotoxicity were evaluated in hamsters (Mesocricetus auratus) after topical application of the liquid gel vehicle (placebo), 1% IGF-1 or 3% IGF-1. No significant difference in the levels of aspartate aminotransferase or alanine aminotransferase was found between the control and treated groups. ELISA did not shown any increase in the plasma level of IGF-1. A haematopoietic niche was found, but it was not associated with myelotoxicity. Efficacy was determined by dermatoscopy analysis of hair density and microscopy analysis of hair diameter, with hair found to be thicker and with more rapid growth in the 3% group than in either the 1% group or the control group. These results strongly suggest that liposomal IGF-1 in a liquid gel formulation is a safe and efficient treatment for hair loss.
 
Castro RF, Azzalis LA, Feder D, et al. Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model. Clinical and Experimental Dermatology 2012;37(8):909-12. Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model - Castro - 2012 - Clinical and Experimental Dermatology - Wiley Online Library

Insulin-like growth factor (IGF)-1 has shown some interesting results in studies examining its use as a hair-loss treatment. IGF-1 works by regulating cellular proliferation and migration during the development of hair follicles. Hepatotoxicity and myelotoxicity were evaluated in hamsters (Mesocricetus auratus) after topical application of the liquid gel vehicle (placebo), 1% IGF-1 or 3% IGF-1. No significant difference in the levels of aspartate aminotransferase or alanine aminotransferase was found between the control and treated groups. ELISA did not shown any increase in the plasma level of IGF-1. A haematopoietic niche was found, but it was not associated with myelotoxicity. Efficacy was determined by dermatoscopy analysis of hair density and microscopy analysis of hair diameter, with hair found to be thicker and with more rapid growth in the 3% group than in either the 1% group or the control group. These results strongly suggest that liposomal IGF-1 in a liquid gel formulation is a safe and efficient treatment for hair loss.

Dose IGF-1 really work?
 
Thymosin Beta 4 for hair loss,


TB-500 Has anyone had any experience with this peptide?



Information:

The first noticable hair regrowth was found on the tester mice;

129_image9.jpg



Schematic effects of thymosin ?4 on stem cells in hair follicles:

F3.medium.gif




There was a topical cream which was developed and gave some interesting results:

serum_ba-2.jpg



hair-growth4.jpg

img-hair-growth5.jpg

img-hair-growth1.jpg

img-hair-growth3.jpg


*All above info is from 'Debris' at hairlosshelp*

Here are some reports to have a look at:

http://www.fasebj.org/content/16/7/691.full.pdf
http://www.fasebj.org/content/early/2004/02/10/fj.03-0244fje.full.pdf


-Annals of the New York Academy of Sciences
Volume 1112, Thymosins in Health and Disease First International Symposium pages 95?103, September 2007

Here is the US patent: "Composition for treatment and prevention of human hair loss and/or hair greying, comprising an effective amount of thymic peptides of the family thymulin, thymosin alpha-1 and thymosin beta-4 and pharmaceutical excipient, diluent or carrier. Method and pharmaceutical composition for treatment and prevention of balding, hair loss, and alopecia."

Patent US20110281802 - Composition for treatment and prevention of hair loss and premature graying ... - Google Patents
 
I'm on the fin and rogaine. About to get the shampoo

Been about 2 weeks. Can't wait to see how this goes
 
Back
Top